Japan’s TransGenic Dropping Knockout Mice For Antibodies
This article was originally published in PharmAsia News
Executive Summary
Instead of its usual practice of concentrating on creating mice with specific genetic defects, Japan's TransGenic is changing to focus more on diagnostics and reagent antibodies. The firm has decided "knockout mice" are too expensive to develop when new technologies are available so it has switched gears and plans instead to focus on licensing marketing rights for its antibodies. Prospective buyers would be makers of diagnostic drugs and reagents. Transgenic's plan is to make its antibody business a greater sales producer than its knockout mice. (Click here for more - a subscription may be required
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.